Overview

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

This study is an open-label, single-Arm， phase II clinical trial of a Chinese Patent Medicine Yangzheng Xiaoji Capsule to improve the adverse reaction nausea of Niraparib in the first-line maintenance treatment in advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan Cancer Hospital and Research Institute

Treatments:

Niraparib